1. Generics Bulletin
  2. >>Business

Viatris Waves Goodbye To API Business

Closes Transaction To Divest API Unit To Matrix; Ongoing Supply Agreement In Place

 
• By Dave Wallace

Viatris has marked another milestone in its ongoing transformation by completing the previously-announced divestment of its active pharmaceutical ingredient business to Matrix Pharma Private Limited in India.

Divested word made of wood
Viatris has divested its API business • Source: Shutterstock

Viatris has completed another stage in the ongoing transformation of its business by closing the divestment of its active pharmaceutical ingredient business to India’s Matrix Pharma Private Limited.

Having in late 2022 earmarked the API business as a “non-core” asset that would be put up for sale – alongside its OTC and women’s healthcare businesses, and after the divestment of its biosimilars business to former partner Biocon (Also see "Viatris To Shed OTC, APIs And Women’s Health As Biocon Deal Nears

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.